AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 163 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,549 | +17.0% | 103 | +33.8% | 0.00% | – |
| Q2 2023 | $2,179 | +23.3% | 77 | 0.0% | 0.00% | – |
| Q1 2023 | $1,767 | -80.9% | 77 | -76.5% | 0.00% | – |
| Q4 2022 | $9,264 | +15.8% | 327 | +14.3% | 0.00% | – |
| Q3 2022 | $8,000 | +166.7% | 286 | +130.6% | 0.00% | – |
| Q2 2022 | $3,000 | -78.6% | 124 | -73.5% | 0.00% | – |
| Q1 2022 | $14,000 | -30.0% | 468 | -20.0% | 0.00% | – |
| Q4 2021 | $20,000 | -48.7% | 585 | -30.9% | 0.00% | – |
| Q3 2021 | $39,000 | -53.6% | 846 | -44.5% | 0.00% | – |
| Q2 2021 | $84,000 | +20.0% | 1,525 | +13.6% | 0.00% | – |
| Q1 2021 | $70,000 | +18.6% | 1,343 | -4.1% | 0.00% | – |
| Q4 2020 | $59,000 | +40.5% | 1,401 | +18.4% | 0.00% | – |
| Q3 2020 | $42,000 | -38.2% | 1,183 | -6.6% | 0.00% | – |
| Q2 2020 | $68,000 | +655.6% | 1,267 | +427.9% | 0.00% | – |
| Q1 2020 | $9,000 | – | 240 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
| Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
| Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
| BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
| Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
| Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
| Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
| BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
| Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
| HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |